APOB and atherosclerosis: These data show that further reduction of plasma cholesterol together with TG lowering to target all apoB-containing lipoproteins may be an effective approach to further reduce existing atherosclerosis in dyslipidemic patients at cardiovascular risk resulting in a further decrease of clinical events and an increase of symptom-free years.